Pure Global AI
NCT05710120Enrolling by invitation

Hepatitis C Screening Alerts

Hepatitis C Screening: HCV Risk Score Alerts in CHORUS™
EpividianClinicalTrials.govother
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
Hepatitis C Screening Alerts in CHORUS™
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Epividian
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 16, 2023
End date
Oct 01, 2023
Enrollment
100000 participants
Primary outcome

Screening to Diagnosis Ratio for Hepatitis C Infection

Summary

The objective of this study is to evaluate whether alerts that identify patients without
 hepatitis C infection to healthcare providers and clinic staff can increase the uptake of
 screening for hepatitis C. A period of time without alerts will be compared to a period of
 time with alerts.

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05710120
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05710120 through Pure Global AI's free database. This phase not specified trial is sponsored by Epividian and is currently Enrolling by invitation. The study focuses on Hepatitis C. Target enrollment is 100000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.